CRGX Form 25 Submitted — Nasdaq Listing/Registration Removal Notice

Rhea-AI Filing Summary

CARGO Therapeutics, Inc. (CRGX) submitted a Form 25 notification to remove a class of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer and exchange and references the Exchange and Issuer compliance provisions under 17 CFR 240.12d2-2(b)/(c). The document does not include a completed signature block, a specific rule box marked to indicate the basis for removal, a removal date, or any explanation of the reason for delisting.

Positive

• None.

Negative

• Form 25 indicates removal/withdrawal from Nasdaq listing/registration for CARGO Therapeutics, Inc.
• Filing lacks key execution details: the signature block is empty and no date or authorized signatory is shown.
• No specific rule box is marked to indicate the precise statutory provision used for the strike/withdrawal in the provided content.
• No reason or effective date for the removal is provided in the submitted text, limiting investor clarity.

Insights

Securities Listing Specialist

TL;DR: Form 25 filed indicating Nasdaq removal/withdrawal process, but key details and signatures are absent.

The filing is a formal notification that CARGO Therapeutics' securities are being removed from listing/registration on Nasdaq, citing the Exchange's compliance with 17 CFR 240.12d2-2(b) and the issuer's compliance with 17 CFR 240.12d2-2(c). The document lacks the actual marked rule provision, an execution signature, and a specific effective or filing date, which limits readers' ability to determine timing and legal basis for the removal. For investors and regulators, the absence of those elements reduces the filing's informational usefulness.

Corporate Governance Analyst

TL;DR: The notice signals delisting activity but omits material procedural details needed to assess impact.

The Form 25 indicates Nasdaq initiated or is processing removal from listing/registration for a class of securities of CARGO Therapeutics, with references to applicable Exchange and SEC rule provisions. However, no explanation for the delisting, no effective date, and no authorized signatory are provided in the text supplied, preventing assessment of governance implications or next steps for stakeholders. This limits stakeholders' ability to evaluate disclosure completeness and compliance timing.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-41859

Issuer:	CARGO Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1900 Alameda De Las Pulgas
	Suite 350
	San Mateo	CALIFORNIA	94403
Telephone number:					(415) 317-4997

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-19	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 for CARGO Therapeutics (CRGX) state?

The Form 25 notifies that a class of CARGO Therapeutics' securities is being removed from listing and/or registration on the Nasdaq Stock Market LLC and references compliance with 17 CFR 240.12d2-2(b) and 12d2-2(c).

Does the filing show why CRGX is being removed from Nasdaq?

No. The provided filing text does not include an explanation of the reason for removal.

Is there an effective date or signature on the Form 25 for CRGX?

No. The supplied content shows an empty signature/date block and does not state an effective removal date.

Which regulatory provisions are cited in the CRGX Form 25?

The filing references 17 CFR 240.12d2-2(b) and 17 CFR 240.12d2-2(c) and lists possible rule provisions under 17 CFR 240.12d2-2(a)(1)-(4).

Does this Form 25 confirm whether the removal is voluntary or mandatory?

The filing text does not specify. It references both Exchange compliance and issuer compliance provisions but does not clearly state whether the withdrawal is voluntary or initiated by the Exchange.